Clinical trials: Stage IIIB Non Small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previously treated with combination chemotherapy that included cisplatin or…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00638937
- Testing
- saracatinib
- Where
- 4 sites in Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H)
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
- Trial name
- IGNYTE (NCT03767348)
- Testing
- RP1, nivolumab
- Where
- 51 sites in United States, France and 3 more
- Volunteers
- 340 people
- Sponsor
- Replimune, Inc.
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Carcinoma, Non-Small-Cell Lung
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study involves a two-part design. Part 1 is designed to evaluate the safety and tolerability of the 4 drug (HLX10+HLX04+carboplatin+pemetrexed).
- Trial name
- NCT03952403
- Testing
- HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin
- Where
- China
- Volunteers
- 643 people
- Sponsor
- Shanghai Henlius Biotech
Lung Cancer
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00117962
- Testing
- cetuximab, carboplatin, pemetrexed disodium
- Where
- 71 sites in United States
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung
Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
- Trial name
- NCT00061646
- Testing
- ABT-510/Thrombospondin-1 mimetic, Carboplatin/Taxol
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Carcinoma, Non-Small-Cell Lung
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without…
- Trial name
- NCT05487391
- Testing
- QL1706 injection, Vinorelbine Tartrate, Paclitaxel
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer, Nonsmall Cell, Stage IIIA, Lung Cancer Non-Small Cell Stage IIIB
Psychosocial eHealth in Advanced Lung Cancer
Being diagnosed with cancer impairs many areas of a person's life. Although efficacious educational, emotional and social interventions exist in this regard, they often reach few survivors and late.
- Conditions
- Lung Cancer, Nonsmall Cell, Stage IIIA, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-Small Cell Stage III, Lung Cancer Stage IV
- Trial name
- NCT05497973
- Testing
- E-health ecosystem of stepped psychosocial care, Usual psychosocial care
- Where
- Spain
- Volunteers
- 152 people
- Sponsor
- Institut Català d'Oncologia
Lung Cancer
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer.
- Trial name
- NCT00002537
- Testing
- topotecan hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)…
- Conditions
- Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT07392073
- Testing
- Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Carcinoma, Non Small Cell Lung
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
- Trial name
- NCT00160069
- Testing
- Sagopilone (BAY86-5302, ZK 219477)
- Where
- 17 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Bayer
Lung Cancer
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061854
- Testing
- soblidotin
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
Lung Cancer
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 is a drug used in the measurement of oxygen in tumor tissue.
- Trial name
- NCT00041028
- Testing
- EF5, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021112
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- 10 sites in Belgium, Germany and 2 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer, Dermatologic Complications
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
- Conditions
- Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
- Trial name
- NCT01416688
- Testing
- assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Where
- 113 sites in United States
- Volunteers
- 146 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, Radiation Toxicity
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00955942
- Testing
- flaxseed
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in treating non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery in patients with human…
- Conditions
- HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02134886
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04181060
- Testing
- Bevacizumab, Biospecimen Collection, Computed Tomography
- Where
- 603 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Stage IB-IIIB NSCLC, Stage IIB-III NSCLC
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy
This is a two-cohort, multicenter, Phase II study to evaluate the efficacy and safety of 3-4 cycles of toripalimab (JS001) plus chemotherapy followed by toripalimab maintenance treatment up to one year in participants with…
- Trial name
- NCT07039656
- Testing
- Toripalimab, Cisplatin-based chemotherapy
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Wen-zhao ZHONG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.